Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05343572 · ClinicalTrials.gov registry record · Early Phase 1
Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium
A Early Phase 1 study of Asherman Syndrome and Atrophic Endometrium, sponsored by Hugh Taylor.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT05343572: Recruiting Early Phase 1 study of Asherman Syndrome and Atrophic Endometrium, sponsored by Hugh Taylor.
NCT05343572 is a Early Phase 1 study of Asherman Syndrome and Atrophic Endometrium that is actively recruiting participants, run by Hugh Taylor. The registered enrollment target is 90 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (70% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05343572, a Early Phase 1 study of Asherman Syndrome and Atrophic Endometrium, is actively recruiting participants, sponsored by Hugh Taylor.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will assess the use of autologous bone marrow stem cells mobilization using 1,1'-\[1,4-phenylenebis-(methylene)\]-bis-1,4,8,11-tetraazacyclotetradecane (PLERIXAFOR) as an effective medical therapy for the treatment of Asherman's Syndrome (AS), Atrophic Endometrium (AE) and Recurrent Implantation Failure (RIF).
Primary Outcome
Change in endometrial thickness post treatment compared to historic controls that received existing standard of care therapy, measured using ultrasound. Thicker endometrium (\>6mm) indicates restoration of endometrial function.
Conditions Studied
Interventions
- DRUG Plerixafor
Study Locations (1)
Connecticut
- Yale Fertility Center - Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2023-11-01 |
| Est. Completion | 2027-12 |
| Phase | Early Phase 1 |
What NCT05343572 shows while recruiting
NCT05343572 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (70% higher).
The record links to 3 conditions, with Asherman Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Plerixafor is the first listed.
NCT05343572 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT05343572 about?
NCT05343572 is a clinical study titled "Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium". This study will assess the use of autologous bone marrow stem cells mobilization using 1,1'-\[1,4-phenylenebis-(methylene)\]-bis-1,4,8,11-tetraazacyclotetradecane (PLERIXAFOR) as an effective medical therapy for the treatment of Asherman's Syndrome (AS), Atrophic Endometrium (AE) and Recurrent Impla...
What is the current status of trial NCT05343572?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 90 participants. The study started on 2023-11-01. Estimated completion is 2027-12.
What conditions does trial NCT05343572 study?
This clinical trial studies the following conditions: Asherman Syndrome, Atrophic Endometrium, Recurrent Implantation Failure.
What interventions are being tested in trial NCT05343572?
The interventions under investigation include: Plerixafor (DRUG).
Who is sponsoring clinical trial NCT05343572?
This trial is sponsored by Hugh Taylor, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05343572 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05343572's enrollment target sits among peer trials
90 233rd of 2000 higher than 1,753 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI